Becaplermin (removed 12/2018)
Increased Rate of Mortality Secondary to Malignancy (removed 12/2018)
- An increased risk of mortality secondary to malignancy was observed in patients treated with three or more tubes of becaplermin gel in a post-marketing retrospective cohort study.
- This drug should only be used when the benefits can be expected to outweigh the risks.
- This drug should be used with caution in patients with known malignancy [See Contraindications and WARNINGS]
FDA and Industry Communications
Patient Counseling Information
Updated November 2022